Want to see TSE:SONA full AI Analyst Report?
Top Page
Sona Nanotech Inc
(SONA)
Select Model
Select Model
Rating:43Neutral
Price Target:
C$0.29
▼(-19.44% Downside)
Action:Reiterated
Date:10/01/26
The score is driven primarily by weak financial performance (no revenue, ongoing losses and cash burn, and negative equity) and a bearish technical setup (price below key moving averages with negative MACD). Valuation provides only modest support because the negative P/E reflects unprofitable operations and no dividend yield is available.
Positive Factors
Proprietary diagnostic nanotechnology
Sona’s proprietary gold nanorod platform targets a specific performance advantage over traditional gold nanoparticles in diagnostic assays. If validated and commercialized, improved sensitivity could support adoption across lateral-flow, immunoassay, and research-use applications, creating a differentiated technology base.
Negative Factors
No revenue generation
Zero reported revenue indicates that Sona has not yet demonstrated commercial monetization of its technology. Without product or licensing revenue, the business remains dependent on funding and future commercialization success, making revenue conversion a major fundamental hurdle over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary diagnostic nanotechnology
Sona’s proprietary gold nanorod platform targets a specific performance advantage over traditional gold nanoparticles in diagnostic assays. If validated and commercialized, improved sensitivity could support adoption across lateral-flow, immunoassay, and research-use applications, creating a differentiated technology base.
Read all positive factors
Sona Nanotech Inc (SONA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$36.84M
Dividend YieldN/A
Average Volume (3M)32.28K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue GrowthN/A
EPS Growth24.65%
CountryCA
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding122,798,620
10 Day Avg. Volume20,836
30 Day Avg. Volume32,279
Financial Highlights & Ratios
PEG Ratio-2.89
Price to Book (P/B)-1.80K
Price to Sales (P/S)0.00
P/FCF Ratio-35.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)N/A
Sona Nanotech Inc Business Overview & Revenue Model
Company Description
Based in Halifax, Canada, Sona Nanotech Inc. is a life sciences company focused on nanotechnology. It develops and commercializes gold nanorod solutions primarily for diagnostic applications. Their product portfolio includes the Nanotech COVID-19 ...
How the Company Makes Money
Sona Nanotech’s primary monetization approach is expected to be the sale and supply of its proprietary gold nanorods (and potentially related reagents/materials) for use by diagnostics and life-sciences customers in assay development and productio...
Sona Nanotech Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
24
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -720.00K | -720.00K | -733.98K | -457.00K | -60.32K | -65.59K |
| EBITDA | -1.90M | -2.72M | -2.00M | -2.02M | -2.34M | -10.38M |
| Net Income | -2.44M | -3.25M | -2.70M | -2.50M | -2.36M | -10.77M |
Balance Sheet | ||||||
| Total Assets | 542.77K | 1.33M | 3.75M | 2.75M | 520.77K | 1.52M |
| Cash, Cash Equivalents and Short-Term Investments | 17.21K | 125.95K | 1.86M | 115.38K | 164.42K | 1.20M |
| Total Debt | 340.16K | 307.74K | 394.67K | 527.68K | 608.47K | 1.34M |
| Total Liabilities | 1.81M | 1.37M | 1.24M | 1.59M | 1.03M | 2.75M |
| Stockholders Equity | -1.26M | -38.78K | 2.51M | 1.16M | -507.86K | -1.22M |
Cash Flow | ||||||
| Free Cash Flow | -894.27K | -1.96M | -1.96M | -1.26M | -1.81M | -3.81M |
| Operating Cash Flow | -894.26K | -1.96M | -1.96M | -1.26M | -1.81M | -3.81M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 14.64K | 0.00 | 0.00 |
| Financing Cash Flow | 521.44K | 228.43K | 3.70M | 1.20M | 778.00 | 4.89M |
Sona Nanotech Inc Technical Analysis
Negative
0.36
Price Trends
0.34
Negative
0.32
Negative
0.36
Negative
Market Momentum
>-0.01
Positive
35.47
Neutral
4.17
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SONA, the sentiment is Negative. The current price of 0.36 is above the 20-day moving average (MA) of 0.35, above the 50-day MA of 0.34, and above the 200-day MA of 0.36, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.47 is Neutral, neither overbought nor oversold. The STOCH value of 4.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:SONA.
Sona Nanotech Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$130.88M | -629.03 | 13.66% | ― | 36.59% | 43.33% | |
47 Neutral | C$47.72M | -14.77 | 12.68% | ― | 45.72% | 35.82% | |
43 Neutral | C$36.84M | -15.42 | 448.05% | ― | ― | 24.65% | |
42 Neutral | C$57.50M | -41.48 | -250.77% | ― | -82.05% | 23.73% |
* Healthcare Sector Average
TSE:SONA
Sona Nanotech Inc
0.33
-0.24
-42.11%
TSE:BUX
BioMark Diagnostics
0.56
0.23
69.70%
TSE:EBM
Eastwood Bio-Medical Canada
1.95
1.52
348.28%
TSE:SZLS.H
StageZero Life Sciences Ltd
0.04
0.00
0.00%
TSE:MIR
Medmira
0.06
-0.03
-33.33%
TSE:ZYUS
ZYUS Life Sciences
0.58
-0.10
-14.71%
Sona Nanotech Inc Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Sona Nanotech Raises $2.5 Million in Over-Subscribed Private Placement
Positive
Aug 10, 2026
Sona Nanotech Inc. has closed an over-subscribed private placement financing, issuing 8,423,372 common shares at $0.30 each to raise approximately $2.53 million in gross proceeds. The securities from this financing are subject to a hold period of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.